Krka has set up an “independent organisational unit” dedicated to biosimilars as part of its stated intention to “embark on the area of similar biological medicines”. Noting that a separate unit had been set up “due to the scale and complexity of content in this field”, the Slovenian firm said it would place a “priority focus on treatments for autoimmune diseases and diabetes”.
“When entering into new and technologically demanding areas such as biosimilar medicines,” a Krka spokesperson told Generics bulletin, “we establish...
